Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
127 Results for "
CBP/P300
" in MedChemExpress (MCE) Product Catalog:
Products (127)
127 Results for "CBP/P300" in MCE Product Catalog:
Target:
Research Areas:
PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
Cat. No.: HY-101125B
CAS No.: 2084850-77-9
Synonyms: D-45
Target:
Research Areas:
D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .
Cat. No.: HY-161959
Research Areas:
EP300/CBP ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). EP300/CBP ligand 1 can be used for synthesis dCE-2 (HY-161958) .
Cat. No.: HY-183817
CAS No.: 2484742-13-2
Research Areas:
GNE-781-COOH is a CBP/p300 degrader. GNE-781-COOH also acts as a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), which can be used to synthesize PROTAC CBP/P300 Degrader-4 (HY-183802) .
Cat. No.: HY-181957
CAS No.: 3082090-83-0
Research Areas:
KB528 is a p300/CBP histone acetyltransferase (KAT) inhibitor with low nM IC50 values against human p300 and CBP, and exhibits selectivity over other KAT family members. KB528 modulates the IRF4 transcriptional network, downregulates the expression of IRF4, MYC, CAV2 and IGLL5, and reduces the protein level of IKZF3. KB528 potently induces apoptosis in multiple myeloma cells. KB528 is applicable to research related to multiple myeloma .
Cat. No.: HY-187436
CAS No.: 3094841-98-9
Research Areas:
CZL-105 is a highly potent, selective, and orally active p300/CBP inhibitor, with IC50 values of 0.09 μM and 0.08 μM against p300 and CBP bromodomains, respectively. CZL-105 inhibits the proliferation of OPM-2 multiple myeloma cells with an IC50 of 57 nM, and induces G0/G1 cell cycle arrest and apoptosis. CZL-105 is applicable for research related to multiple myeloma .
Cat. No.: HY-P11829
Target:
Research Areas:
Cat. No.: HY-184556
Research Areas:
dCBP-30 is an orally active, selective and dual-acting CBP/p300 PROTAC degrader with DC50 values of 0.05 nM (CBP) and 0.04 nM (p300), respectively. dCBP-30 reduces the acetylation levels of histone substrates H3K27, H3K18, H2BK5 and H2BK20, downregulates multiple myeloma-specific dependency programs, and induces multiple myeloma cell apoptosis. dCBP-30 triggers tumor regression and prolongs survival in multiple myeloma xenograft mouse models, and exhibits synergistic antiproliferative activity with dexamethasone. dCBP-30 can be used for the research of multiple myeloma .
Cat. No.: HY-184454
Research Areas:
CBP/p300 ligand 11 is a ligand of EP300 and CBP, which can be used for PROTAC synthesis, such as serving as the target protein ligand of PROTAC CBP/EP300 Degrader-5 (HY-184453) .
Cat. No.: HY-107455R
CAS No.: 1889279-16-6
Research Areas:
A-485 (Standard) is the analytical standard of A-485 (HY-107455). This product is intended for research and analytical applications. A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively .
Cat. No.: HY-183251
Research Areas:
PROTAC p300 degrader-1 is a paralog-selective, PROTAC-based degrader targeting the p300/CBP protein. It exhibits potent antiproliferative, cell cycle arrest and pro-apoptotic activities, and can be used in the research and development of antitumor drugs and related mechanism studies for hematological malignancies (AML, MM, NHL) .
Cat. No.: HY-111784R
CAS No.: 2222941-37-7
Synonyms: CCS1477 (Standard)
Research Areas:
Inobrodib (Standard) is the analytical standard of Inobrodib (HY-111784). This product is intended for research and analytical applications. Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .
Cat. No.: HY-183992
CAS No.: 3094772-96-7
Research Areas:
CZL-149 is an orally active dual BET and p300/CBP bromodomains inhibitor with IC50s of 13 nM and 10.5 nM for BED4 BD1 and p300, respectively. CZL-149 reduces c-Myc and H3K27Ac levels. CZL-149 has good drug-like properties and metabolic characteristics, as well as good safety. CZL-149 can be used for the study of multiple myeloma .
Cat. No.: HY-184124
Research Areas:
JYZ3032 is an orally active super inhibitor of androgen receptor (AR) and p300/CBP. JYZ3032 redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR-driven transcription and proliferation. JYZ3032 induces deep and durable tumor regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer .
Cat. No.: HY-15826R
CAS No.: 1613695-14-9
Research Areas:
SGC-CBP30 (Standard) is the analytical standard of SGC-CBP30 (HY-15826). This product is intended for research and analytical applications. SGC-CBP30, a chemical probe, is a potent and highly selective CBP/p300 bromodomain (Kds of 21 nM and 32 nM for CBP and p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)] bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .
Cat. No.: HY-168463
CAS No.: 3109988-90-8
Research Areas:
Y16524 is a potent inhibitor of CBP/p300 bromodomain , with the IC50 of 0.01 μM. Y16524 has the potential for the research of acute myeloid leukemia (AML) .
Cat. No.: HY-100697R
CAS No.: 2018300-62-2
Research Areas:
TPOP146 (Standard) is the analytical standard of TPOP146 (HY-100697). This product is intended for research and analytical applications. TPOP146 is a selective CBP/P300 benzoxazepine bromodomain inhibitor with Kd values of 134 nM and 5.02 μM for CBP and BRD4.
Cat. No.: HY-180804
CAS No.: 3032444-06-4
Research Areas:
CZL-077 is a potent, selective, and orally active p300/CBP bromodomain (BRD) inhibitor (p300 IC50 = 0.034 μM, CBP IC50 = 0.052 μM) exhibiting high selectivity over the BRDs of BET proteins (BRD2/3/4). CZL-077 inhibits cell growth with IC50 values of 0.024 μM and 5.6 μM in OPM-2 and 22RV1 cells, respectively. CZL-077 shows antitumor efficacy in OPM-2 and 22RV1 xenograft mouse models. CZL-077 can be used for multiple myeloma and prostate cancer research .
Cat. No.: HY-184453
Research Areas:
PROTAC CBP/EP300 Degrader-5 is a CBP and EP300 PROTAC degrader. PROTAC CBP/EP300 Degrader-5 relies on the ubiquitin-proteasome pathway to preferentially induce ubiquitination and degradation of EP300 rather than CBP. PROTAC CBP/EP300 Degrader-5 induces G1 phase cell cycle arrest and triggers Apoptosis. PROTAC CBP/EP300 Degrader-5 is applicable to research related to EP300-dependent malignant tumors .
Cat. No.: HY-165413
CAS No.: 1392224-35-9
Target:
Research Areas:
KST012174 hydrochloride is a potent HIF-1α-p300/CBP interaction inhibitor with an IC50 of 107 μM. KST012174 hydrochloride completely blocks the binding of HIF-1α to p300 protein at a concentration of 100 μM, without affecting the expression stability of HIF-1α protein itself. By directly interfering with the binding between the C-terminal transactivation domain (C-TAD) of HIF-1α and the CH1 domain of p300, KST012174 inhibits the transcriptional activation function of HIF-1α, thereby significantly downregulating the mRNA expression level of its downstream target gene VEGF and exerting core activity in inhibiting tumor angiogenesis. KST012174 hydrochloride is applicable for research on cancer occurrence and development as well as hypoxia pathway-targeted strategies .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
